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ABSTRACT Monoclonal antibody 104 recognizes a subset
of amphibian nuclear granules (B-snurposomes) and active
sites of RNA polymerase II transcription in vertebrates and
invertebrates. Monoclonal antibody 104 reacts with a set of
nuclear serine- and arginine-rich phosphoproteins (SR family)
with strikingly conserved apparent molecular masses. The
most abundant family members in human (SRp33) and Droso-
phila (SRp55) cell lines can replace one another as essential
splicing factors in a human cell-free system. Each of these
polypeptides can functionally replace human SF2, an essential
splicing factor that also regulates 5' splice site selection of
alternatively spliced pre-mRNAs in vito. Drosophila SRp55
also functions as an alternative splicing factor in the human
cell-free system. Analysis of cloned cDNAs shows that SRp55
and SF2 are highly related and reveals regions of similarity to
genetically defined regulators of alternative splicing in Droso-
phUa. These results suggest that the conserved SR family of
phosphoproteins, which includes SRp55 and SF2, is involved in
constitutive pre-mRNA splicing and in the specificity of alter-
native splice site selection.
Alternative pre-mRNA splicing is a widespread mechanism
for generating structurally and functionally distinct protein
isoforms (1, 2). SF2 is a human protein essential for the first
RNA cleavage-ligation step in general pre-mRNA splicing
(3-5); the concentration of this factor also determines which
5' splice site is selected in pre-mRNAs containing alternative
sites (5-8). A human 33-kDa protein doublet has SF2 activity
and can complement SF2-deficient extracts for the formation
or stabilization of specific pre-spliceosome complexes (4).
When pre-mRNAs containing alternative 5' splice sites are
spliced in vitro, SF2, also known as alternative splicing factor
(ASF) (8), is able to influence which splice site is used; high
and low concentrations of SF2 result in preferential use of
proximal or distal 5' splice sites, respectively (6, 8). Human
cDNAs encoding SF2/ASF were recently isolated using
DNA probes derived from the amino acid sequence of the
purified protein (5, 7). The full-length cDNAs encode a
polypeptide with a predicted molecular mass of 28 kDa,
which contains an RNA recognition motif (RRM) (9, 10), and
a region rich in arginine-serine dipeptides (RS domain). The
anomalous electrophoretic mobility and heterogeneous ap-
pearance of SF2 are due to phosphorylation (refs. 5 and 7;
A.M. and A.R.K., unpublished data).
Characterization of proteins that interact with active sites
of RNA polymerase II transcription in amphibian germinal
vesicles led to the identification ofthe SR family ofconserved
serine- and arginine-rich nuclear phosphoproteins (11, 12).
These studies began with the characterization of monoclonal
antibody 104 (mAb 104), raised against Xenopus laevis
oocyte nuclear proteins (11). mAb 104 cross-reacts widely
throughout the animal kingdom and stains active sites of
RNA polymerase II transcription on the lateral loops of
amphibian lampbrush chromosomes (11) as well as puffs on
Drosophila polytene chromosomes (12). mAb 104 also stains
a subset of nuclear granules (B-snurposomes) in amphibian
oocytes (11, 13) and the nucleoplasmic speckled network in
vertebrate cells (12, 14). These nuclear substructures contain
many splicing components and are thought to be sites of
pre-mRNA processing (11-17).
mAb 104 recognizes a family of nuclear phosphoproteins
with strikingly conserved apparent molecular masses of 20,
30, 40, 55, and 75 kDa§ in the somatic tissues of various
animal cells (12). These proteins have highly characteristic
solubility properties in ammonium sulfate and magnesium
chloride solutions (12). The most abundant SR family mem-
ber in Drosophila Kc cells is the 55-kDa polypeptide, termed
SRp55 (12). Drosophila cDNA clones encoding SRp55 and a
closely related variant, known as B52, were recently isolated
(12, 18). The SRp55 open reading frame encodes a 39-kDa
protein; the difference between apparent and actual molec-
ular mass is largely due to phosphorylation (12). Drosophila
SRp55, like human SF2, contains an RRM and an RS domain.
The presence of similar sequence elements in human SF2 and
Drosophila SRp55, and their similar fractionation properties,
prompted us to examine whether SF2 belongs to the SR
family and whether SRp55 is also a splicing factor.
MATERIALS AND METHODS
Protein Purification. To purify Drosophila SRp55, whole
cell extracts from 1010 Kc cells were fractionated by precip-
itation with ammonium sulfate essentially as described (12).
The fraction that precipitated between 65% and 90% of
saturation was dialyzed and incubated on ice for 1 hr in 20
mM magnesium chloride, and the precipitated proteins were
recovered by centrifugation (12). The pellet was fractionated
by preparative SDS/PAGE, and the prominent mAb 104
immunoreactive 55-kDa protein was excised, eluted, and
renatured in the presence of guanidinium hydrochloride and
carrier acetylated bovine serum albumin, as described (19).
The renatured protein was concentrated again by magnesium
precipitation (12) and resuspended in splicing extract buffer
(3). Human SRp33 was purified from 5 x 108 HeLa cells by
the same method. Chromatographic purification ofHeLa SF2
by functional complementation was as described (4). Purified
polypeptides were analyzed by SDS/PAGE and stained with
Coomassie blue (20).
Pre-mRNA Substrates. Radiolabeled pre-mRNA substrates
were prepared by transcription with SP6 RNA polymerase in
the presence ofcap analogue, as described (3). Wild-type and
thalassemic ,3-globin pre-mRNAs were made from pSP64-
Hf3A6 and pSP64-HI3A6IVS1-1A DNA templates (21) linear-
Abbreviations: mAb, monoclonal antibody; RRM, RNA recognition
motif; ASF, alternative splicing factor; snRNP, small nuclear ribo-
nucleoprotein particle.
tTo whom reprint requests should be addressed.§Approximate molecular masses to the nearest 5 kDa, as given in ref.
12; a value of 33 kDa is used here instead of 30 kDa.
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ized with BamHI.- SP6 RNA polymerase, restriction enzyme,
and cap analogue were from New England Biolabs.
Extract Preparation and Assay Conditions. The preparation
of nuclear and cytoplasmic 5100 extracts, splicing reaction
conditions, RNA extraction, and urea/PAGE analysis were
according to published procedures (3-5, 21).
RESULTS
Comparison of SRp55 and SF2 Amino Acid Sequences.
Comparison ofthe predicted protein sequences ofhuman SF2
(28 kDa) and Drosophila SRp55 (39 kDa) reveals identities in
123 of 248 amino acids in SF2 (50%) and conservative
substitutions in 18 additional amino acids (Fig. 1). Human
SF2 and Drosophila SRp55 contain an N-terminal RRM and
a C-terminal RS domain. Similar sequence motifs are found
singly or in combination in the genetically defined Drosophila
alternative splicing regulators transformer (23), transform-
er-2 (24, 25), Sex-lethal (26), and suppressor-of-white-apricot
(27) and in the 70-kDa polypeptide of the essential splicing
factor Ul small nuclear ribonucleoprotein particle (snRNP)
(9, 28, 29). The sequence similairities of these proteins to SF2
and to SRp55 are limited to the degenerate RRM and/or RS
domains and have been previously noted (5, 7, 12). In
contrast, the similarity between SF2 and SRp55 is much more
extensive, both within and beyond the RRM and RS domains.
Human SF2 and Drosophila SRp55 have very similar,
though not identical, RRMs that include the two conserved
submotifs known as RNP-1 and RNP-2 (10, 22); the spacing
between RNP-2 and RNP-1 is 30 amino acids in SF2 and 25
amino acids in SRp55. The two unusual prolines in the RNP-1
element of SF2 correspond to asparagine and glycine in
SRp55; most RRM proteins contain arginine or lysine fol-
lowed by glycine at these positions (9, 10, 22). The octapep-
tide EFEDPRDA, which overlaps the RNP-1 element of SF2,
is identical to an octapeptide of unknown function that
precedes the RRM ofhuman and Xenopus Ul snRNP 70-kDa
polypeptide (9, 28). Drosophila SRp55 contains the highly
related sequence EFEDYRDA at a position homologous to
that in SF2 (Fig. 1). The Drosophila 70-kDa homologue
contains the less homologous but still related sequence
DFEDPKDT preceding its RRM (29).
Both human SF2 and Drosophila SRp55 contain RS do-
mains that occur primarily as consecutive RS dipeptides.
Most of the length difference between the two proteins is
accounted for by a longer basic region that includes the RS
domain of SRp55 (Fig. 1).- Both proteins are extremely basic
in their unphosphorylated state: their theoretical isoelectric
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points are 10.77 and 11.92, respectively. Like the Ul 70-kDa
polypeptide (9, 28, 29), they contain glycine-rich stretches
that may function as flexible hinges separating the RRM and
RS domains. The extensive homology between SF2 and
SRp55 also includes additional peptides not found in any
other proteins in the current databases--e.g., amino acids
111-125 and 133-151 in the human SF2 sequence (Fig. 1).
Purification and Functional Characterization of SR Pro-
teins. In addition to the extensive sequence homology be-
tween human SF2 and Drosophila SRp55, HeLa SF2 purified
by functional complementation is recognized by mAb 104 in
immunoblots, suggesting that SF2 is the 33-kDa SR family
member (data not shown). mAb 104 does not recognize
recombinant SF2 produced in Escherichia coli (data not
shown; ref. 5), consistent with the previous finding that this
antibody is specific for a phosphoepitope shared among the
SR family members (11, 12). A further indication that SF2
belongs to the SR family is the fact that extracts deficient in
SF2 activity are prepared by ultracentrifugation in the pres-
ence of 4.5 mM magnesium chloride, conditions that were
later shown to sediment the entire SR protein family (3, 12).
Highly purified SF2 also displays this unusual insolubility in
magnesium chloride (data not shown).
The functional conservation of several splicing activities,
including SF2, between humans and Drosophila has been
noted in biochemical complementation experiments with
partially purified fractions (ref. 30; C. Siebel and D. Rio,
personal communication). To determine if SRpS5 is function-
ally related to SF2, we purified SRpSS from Drosophila Kc
cells by ammonium sulfate fractionation, followed by mag-
nesium-induced precipitation (12). The prominent SRp55
polypeptide was purified further by preparative SDS/PAGE,
renatured, and concentrated (Fig. 2, lane 3). The human mAb
104 immunoreactive SRp33 polypeptide, which may be iden-
tical to SF2., was similarly purified from HeLa cells to
determine if it has SF2 activity (lane 2). This procedure yields
highly purified SR polypeptides', except for the presence of
carrier acetylated bovine serum albumin. Gel-'purified Dro-
sophila SRp55 and human SRp33 and chromatographically
purified human SF2 (lane 1) (4) were tested for the ability to
complement an SF2-deficient, splicing-inactive S100 extract
(3, 4) from HeLa cells (Fig. 3).
All three preparations efficiently complemented the S100
extract (which provides all other essential splicing factors but
lacks SF2 activity) to splice a wild-type human (3-globin
pre-mRNA (Fig. 3, lanes 2-5). Control gel-purified fractions
lacking SRp55 or SRp33 but containing carrier acetylated
bovine serum albumin had no activity (data not shown). A
RNNP-i1
MSGGGVIRG-PAGNNDCQIUUN PDVSTKRIoDHK A O SGGPPFA~lr p ~ GDYY
Vn GIEYGV ER'L RF KG RT' Li- GYG YUI1DIW1ATELNIKEL L
YELRMFH GTG~ GG APPRG SRHEVSRPG HEDC
EVVPA G A- R RY D Y RR R NE S S LI -TIJY L LiIEN SSRV sYIJOLK Ef TI
VY-DT VKr"YVi NK -- HSmEGDTAYIRVKVDRPRHPSYG----M
'AHKQ-RNE ASLSIRlKTRS
1. ....: SRSKSRSRSKSRGGRSKSKSPVK~
----------MSMYMjSSG ---PRYIP-HUB T
KSRD VS KSKS KS HM TI R KIE iD RSR TRS V K8Fu"IEISKS
HRDSRSR DR SASA ENKSRSRSRSRPSAS PKNGNASP DRNN ESMDD
FIG. 1. Primary sequence homology between human SF2 and Drosophila SRp55. The complete amino acid sequences of human SF2 (H.
SF2) (5, 7) and Drosophila SRp55 (D. SRp55) (12, 18) are shown in the one-letter code. Amino acid identities are indicated in reverse type; amino
acid similarities are shown in stippled boxes; dashes denote gaps introduced to maximize homology. Amino acid positions in each protein are
shown on the right. The conserved RNP-1 and RNP-2 elements ofthe RRM (9, 10,22) are indicated by solid bars. The alignment shown preserves
the RRM homology and minimizes the number of gaps (nine in H. SF2, two in D. SRp55).
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FIG. 2. Purification of human and Drosophila SR and SF2
polypeptides. Lane M, molecular mass markers (in kDa); lane 1, 28
Al of chromatographically purified human SF2 preparation; lane 2, 4
gl of gel-purified and renatured human SRp33; lane 3, 4 IL of
gel-purified and renatured Drosophila SRp55. The molecular masses
of the markers and the positions of the 33-kDa and 55-kDa mAb 104
antigens and of carrier bovine serum albumin (BSA) are indicated.
Chromatographically purified HeLa SF2 appears heterogeneous
because of differences in phosphorylation and because of the pres-
ence of a 32-kDa polypeptide unrelated in sequence (4, 5).
comparison of splicing efficiencies (Fig. 3, lanes 4 and 5) and
protein concentrations (Fig. 2, lanes 2 and 3) shows that gel-
purified Drosophila SRp55 has a somewhat higher specific
activity than human SRp33. The control chromatographically
purified human SF2 has considerably higher specific activity
(Fig. 2, lane 1; Fig. 3, lane 3). The apparent stoichiometry of
SF2 relative to pre-mRNA has been previously measured (5).
The variable specific activities observed here most likely
result from incomplete renaturation ofthe gel-purified proteins
and/or from their different phosphorylation states.
To determine if Drosophila SRp55 can also influence
alternative splicing in the heterologous in vitro system in a
concentration-dependent manner, a 83-thalassemic human
pre-mRNA was employed (5, 31). In this mutant substrate,
the 5' splice site is inactive, and three cryptic 5' splice sites
(cr.1, cr.2, and cr.3) are available for alternative splicing to
the authentic 3' splice site. cr.1, cr.2, and cr.3 exist in linear
order from 5' to 3' direction on the pre-mRNA. In the
presence of constant amounts of S100 extract, the efficiency
of splicing of the mutant pre-mRNA increased in proportion
to the amount of purified SRp55 added (Fig. 3, lanes 7-10).
A gradual switch from utilization of cr.2 to cr.3 was observed
as the concentration of SRp55 was increased. This is seen as
an increase in the ratio ofcr.3 to cr.2 spliced mRNA (lane 10)
and is comparable to the effect of human SF2 on the same
pre-mRNA (5, 6). A similar stimulation of proximal alterna-
tive 5' splice sites upon increasing the concentration of
SRp55 was observed with 3-globin pre-mRNA derivatives
containing either a duplicated authentic first intron 5' splice
site or a proximal simian virus 40 small tumor antigen 5' splice
site (data not shown). We conclude that Drosophila SRp55
can functionally replace human SF2 in vitro and thus can
interact with other human splicing factors to catalyze splicing
and to influence alternative 5' splice site selection.
DISCUSSION
We have shown that human SF2 and Drosophila SRpS5 have
extensive amino acid sequence homology (Fig. 1), whereas
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FIG. 3. Drosophila SRp55 can replace human SF2 in a human
cell-free system. Wild-type (8wt; lanes 1-5) or P-thalassemic (fithal;
lanes 6-10) pre-mRNAs containing the first two exons and first intron
of human P-globin were spliced in vitro with the indicated extracts
and fractions in 25-IAI reaction mixtures containing 15 1A of extract
and splicing extract buffer. Lane 1, 8 pul of HeLa nuclear extract
(NE); lane 2, 7 pl of S100; lane 3, 7 Al of S100 plus 8 pA of
chromatographically purified HeLa SF2; lane 4, 7 ul of S100 plus 8
y1 of gel-purified human SRp33; lane 5, 7 A.l of S100 plus 8 pul of
gel-purified Drosophila SRp55; lane M, Hpa II-digested pBR322
molecular mass markers; lane 6, HeLa nuclear extract; lanes 7-10,
7 pJ of S100 plus 0, 2, 4, or 8 pul of gel-purified Drosophila SRp55,
respectively.
the similarity among either of these proteins, U1 70-kDa,
known Drosophila splicing regulators, and the large family of
RRM proteins, is more limited. However, we do not think
that SF2 and SRp55 are true homologues, since human and
Drosophila cell lines both have 33- and 55-kDa SR family
members, albeit with different abundances (12). When human
SF2 was first identified as a 33-kDa polypeptide doublet,
secondary chromatographic peaks of SF2 activity were also
reported, some of which contained a 55-kDa polypeptide (4).
A polypeptide of the same size was also detected by immu-
noprecipitation of 35S-labeled HeLa extracts with anti-SF2
antiserum (4). However, this polypeptide could not be char-
acterized further because of its low abundance. More re-
cently, partial amino acid sequence ofhuman SRp55 isolated
by the methods described here shows that it is more closely
related to Drosophila SRpS5 than to human SF2 (A.M.Z., W.
Lane, and M.B.R., unpublished data). The slight difference
in molecular mass between human SRp33 and SF2 (Fig. 2) is
probably due to variable extents of phosphorylation in the
two preparations and is consistent with the heterogeneity
previously observed upon in vitro translation ofa cloned SF2
cDNA and with the even greater electrophoretic mobility of
unphosphorylated recombinant SF2 (5). However, it is pos-
sible that additional SR family members with molecular mass
and activity similar to SF2 are also present in the purified
SRp33 preparation.
A nearly identical variant of Drosophila SRp55, termed
B52, has recently been described (18). The two proteins differ
at 11 sites of apparent polymorphism, and, in addition, B52
pc 5kL:
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contains a 21-amino acid insertion near the C terminus, which
may arise by alternative splicing (12, 18). B52 is associated
with interbands and puffs on Drosophila polytene chromo-
somes and can be UV cross-linked to nucleic acids in vivo
(18). Another putative member of the SR family, perhaps
SRp2O, is rbpl, a 15-kDa Drosophila protein of unknown
function, which has an RRM strikingly similar to that of
human SF2 as well as an RS domain and the octapeptide
EFEDRRDA (Y.-J. Kim and B. S. Baker, personal commu-
nication). Alternatively spliced cDNA variants of ASF-1
(SF2) encoding open reading frames of 22 kDa (ASF-3) and
32 kDa (ASF-2) have been described (7); the apparent mo-
lecular mass of in vitro translated ASF-2 is 40 kDa. Despite
their size similarity to SR family members, the presumptive
ASF-2 and ASF-3 polypeptides lack RS domains (7).
The biochemical effects of Drosophila SRp55 on general
splicing and on alternative 5' splice site selection in a human
cell-free system are identical to the effects of human SF2
(Fig. 3). These results, together with the striking primary
sequence homology between the two proteins (Fig. 1), sug-
gest that they are functionally related. Additional members of
the SR protein family may also turn out to have similar
functions, and it will be of interest to determine the signifi-
cance of this apparent functional redundancy. The finding
that at least two members of the evolutionarily conserved SR
family ofphosphoproteins function as general and alternative
splicing factors in vitro suggests that the control of gene
expression by alternative splicing may involve tissue-specific
and developmental regulation of the concentrations or activ-
ities of each of these phosphoproteins. Future experiments
should address the importance ofthe phosphorylation state of
these proteins, their relative abundances in different cells,
and whether each member of the SR family has unique
functional properties.
Previous studies have localized one or more SR family
members to chromosomal sites of transcription (11, 12, 18)
and to snurposomes and speckles (11, 13). Our finding that at
least two of these proteins in Drosophila and humans are
splicing factors is consistent with the views that splicing is a
cotranscriptional phenomenon (13, 32), and that snurpo-
somes and speckles are involved in splicing as spliceosome
assembly or as storage sites (11-17).
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